C-Peptide Blood Test

What Does This Test Measure?

C-peptide is a protein fragment cleaved from proinsulin when insulin is produced. It is released in equimolar amounts with insulin but is not extracted by the liver (unlike insulin), making it a more accurate measure of endogenous insulin production. C-peptide is the gold standard for distinguishing type 1 from type 2 diabetes.

Why Your Doctor Ordered This Test

Clinicians order C-peptide primarily when they need to determine how much insulin a patient’s pancreas is actually producing. This is most urgent in two scenarios: first, when a new diabetes diagnosis is ambiguous, for example, a lean 35‑year‑old presenting with an A1c of 9.2% and no ketoacidosis could have either type 1 diabetes with residual beta‑cell function or early type 2 diabetes. A fasting C‑peptide drawn with a simultaneous glucose quickly separates them: a C‑peptide >1.0 ng/mL in the face of hyperglycemia points toward type 2, while a low or undetectable level favors type 1. The test is also used periodically in established diabetes to monitor beta‑cell reserve; a falling C‑peptide in a person with type 2 signals that oral agents may soon be insufficient and insulin therapy should be started. After pancreas or islet transplantation, serial C‑peptide measurements confirm graft survival.

The second major indication is the workup of spontaneous hypoglycemia. When a patient has documented low blood glucose (<55 mg/dL), measuring C‑peptide during the hypoglycemic episode tells the doctor whether the low sugar is driven by excessive endogenous insulin (insulinoma, nesidioblastosis, or sulfonylurea use) or by exogenous insulin injection. In exogenous insulin‑induced hypoglycemia, insulin is high but C‑peptide is suppressed because commercial insulin preparations contain no C‑peptide. Conversely, insulinoma causes both high insulin and high C‑peptide. The test is also sometimes ordered alongside a mixed‑meal tolerance test in post‑bariatric surgery patients to assess for hyperinsulinemic hypoglycemia, and in polycystic ovary syndrome to quantify the degree of insulin hypersecretion driving androgen excess.

What High C-Peptide Means

High C-peptide indicates high endogenous insulin production: type 2 diabetes with insulin resistance (most common cause; pancreas is working hard to overcome resistance), insulinoma (very high C-peptide with low glucose), Cushing syndrome, and acromegaly.

What Low C-Peptide Means

Low C-peptide indicates low endogenous insulin production: type 1 diabetes (autoimmune destruction of beta cells, very low or undetectable C-peptide), advanced type 2 diabetes with beta-cell failure, and factitious hypoglycemia from exogenous insulin injection (low C-peptide because injected insulin contains no C-peptide, distinguishing it from insulinoma where C-peptide is high).

How to Prepare and What Affects the Result

The standard C‑peptide measurement requires an 8‑ to 12‑hour fast (water allowed), and it must be drawn simultaneously with a plasma glucose sample. In some evaluations, a non‑fasting or stimulated C‑peptide is obtained (for example, during a mixed‑meal tolerance test or after a glucagon injection) in which case the timing of the blood draw is dictated by the specific protocol. Biotin (vitamin B7) supplements, even in moderate doses, can falsely lower or raise C‑peptide results depending on the immunoassay platform; patients should stop taking biotin at least 48 hours before the test. Corticosteroids, oral contraceptives, and antipsychotics that promote insulin resistance can elevate C‑peptide by driving compensatory hypersecretion. Sulfonylureas and meglitinides stimulate insulin release and will raise C‑peptide; ideally these are withheld on the morning of the test after consulting the prescribing physician.

The sample is collected in a serum or heparin‑plasma tube and should be centrifuged and separated within one hour because prolonged contact with red cells can cause degradation. Hemolyzed specimens may produce unreliable results and should be rejected. C‑peptide is stable in separated serum for several days refrigerated and for weeks frozen; laboratories typically freeze samples if analysis is delayed. It is important that the laboratory uses an assay standardized against the international reference preparation (IRP), as numerical results can vary across methods. Because C‑peptide is cleared by the kidneys, patients with chronic kidney disease need a simultaneous creatinine or eGFR measurement to avoid misinterpreting an elevated C‑peptide caused solely by reduced renal clearance.

Common Misinterpretations

A common mistake is interpreting a C‑peptide result without a simultaneous glucose value. A C‑peptide of 2.5 ng/mL looks comfortably normal, but if the accompanying glucose is 45 mg/dL, the pancreas should be completely suppressed, so that “normal” C‑peptide is actually inappropriately high and strongly suggests an insulinoma or sulfonylurea overdose. Conversely, a C‑peptide of 0.5 ng/mL appears low, but if glucose is also low, the finding is appropriate (the body is simply not making insulin in the face of hypoglycemia). This misreading leads to missed insulinomas or unnecessary imaging. Renal impairment is another major confounder. Because C‑peptide is cleared by the kidneys, any reduction in glomerular filtration rate causes C‑peptide to accumulate, mimicking endogenous hyperinsulinemia. A patient with stage 3 chronic kidney disease may have a fasting C‑peptide of 6 ng/mL with completely normal insulin secretion; without an eGFR, the clinician might incorrectly diagnose insulin resistance or a tumor.

Another error is equating a high C‑peptide with insulin resistance. C‑peptide reflects secretion, not sensitivity. A high value means the beta cells are pumping out insulin, but it does not tell you whether the body is responding to it. In early type 2 diabetes, high C‑peptide often indicates compensatory hypersecretion in the setting of resistance, but in Cushing syndrome or acromegaly, elevated C‑peptide accompanies increased insulin secretion driven by counter‑regulatory hormones, not primary insulin resistance. Furthermore, a low C‑peptide is frequently mislabeled as type 1 diabetes when it can represent burned‑out type 2 diabetes with near‑total beta‑cell failure. The clinical history, autoantibody testing, and age of onset help differentiate these etiologies. Finally, exogenous insulin injection causes high measured insulin with low C‑peptide, a pattern that is sometimes misinterpreted as a lab error if the possibility of surreptitious insulin use is not considered.

Frequently Asked Questions

What does a high C-peptide level mean?

A high C‑peptide level indicates that your pancreas is producing a large amount of insulin. The most common reason is insulin resistance in type 2 diabetes, where the body needs more insulin to keep glucose normal. Other causes include insulinoma (a rare insulin‑producing tumor), Cushing syndrome, acromegaly, and sulfonylurea medication use. To interpret the result correctly, a simultaneous blood glucose measurement is essential; high C‑peptide with low glucose is suspicious for insulinoma, while high C‑peptide with high glucose points to type 2 diabetes.

What does a low C-peptide level mean?

A low C‑peptide level means your pancreas is making little or no insulin. The classic cause is type 1 diabetes, where the immune system destroys insulin‑producing beta cells, leading to very low or undetectable C‑peptide. Advanced type 2 diabetes can also lead to beta‑cell failure and low C‑peptide. Another key scenario is hypoglycemia caused by injecting too much exogenous insulin, because pharmaceutical insulin does not contain C‑peptide, a low C‑peptide in the setting of low glucose and high insulin strongly suggests surreptitious insulin use rather than an insulinoma.

Why is C-peptide tested instead of insulin?

C‑peptide is tested instead of insulin because it provides a more accurate picture of the body’s own insulin production. Insulin is heavily extracted by the liver on its first pass, so levels in peripheral blood do not fully reflect secretion. In addition, exogenous insulin cannot be distinguished from endogenous insulin by standard insulin assays, whereas C‑peptide is absent from commercial insulin preparations. Moreover, C‑peptide has a longer half‑life and is less prone to rapid fluctuations, making it a more stable marker for assessing beta‑cell function over time.

How do I prepare for a C-peptide test?

You typically need to fast for 8–12 hours before a C‑peptide blood draw, drinking only water. A simultaneous glucose sample is usually taken. Stop biotin supplements 48 hours ahead because they can interfere. Medications such as sulfonylureas, corticosteroids, and oral contraceptives can affect levels, do not stop prescribed drugs without guidance, but inform your provider about them. For post‑bariatric surgery evaluation, a mixed‑meal tolerance test may be used instead of fasting; follow your clinic’s specific protocol regarding timing and food intake.

Can kidney disease affect C-peptide results?

Yes, kidney disease can falsely elevate C‑peptide because the kidneys clear C‑peptide from the blood. In chronic kidney disease, reduced glomerular filtration rate causes C‑peptide to accumulate, even if insulin production is normal. A patient with stage 3 or 4 CKD may have a fasting C‑peptide of 5 ng/mL or higher without any insulin hypersecretion. To avoid misdiagnosis of insulin resistance or insulinoma, any C‑peptide result in someone with renal impairment must be interpreted alongside an eGFR measurement and a simultaneous glucose level.

Related Markers: Read Together for Full Context

BloodWorker reads lab values together, not in isolation. These related markers provide essential context for interpreting your C-Peptide result: